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Abstract: The application and utility of melanoma sentinel lymph node biopsy (SLNB) has evolved significantly since its
inception over two decades ago. The current focus has shifted from a staging modality to potentially a therapeutic interven-
tion. Recent research to include large multi-institutional randomized trials have attempted to answer the question: is a com-
pletion lymph node dissection (CLND) required following a positive SLNB? This review provides an evidence-based,
contemporary review of the utility of CLND for SLNB positive head and neck cutaneous melanoma patients.
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INTRODUCTION
The incidence of melanoma continues to climb at
staggering rates with 87,110 new invasive cases pro-
jected in the United States for 2017 and an additional
9,730 melanoma deaths this same year.1 Regional metas-
tasis remains the most important prognostic factor for
melanoma recurrence and survival which underscores
the importance of accurate staging.2 Up to 20% of mela-
noma patients presenting with localized stage I and II
disease will actually harbor occult regional metastasis
despite a clinically and radiographically N-0 neck. For
this reason, Dr. Donald Morton introduced the sentinel
lymph node biopsy (SLNB) technique in 1992 as a means
to identify these patients with aggressive melanoma who
may benefit from additional therapy to include comple-
tion lymphadenopathy (CLND) and adjuvant therapy.3
Since its inception, SLNB has replaced elective neck
(END) as standard of care for staging of localized mela-
noma because four prospective randomized trials failed to
demonstrate a survival benefit with END.4–7 Ultimately
head and neck (HN) SLNB emerged as a reliable staging
modality, more so than END and alternative imaging tech-
niques. In the ensuring two decades, SLNB was formally
incorporated into American Joint Committee on Cancer
staging system2 as well as evidenced-based national8–10
and international guidelines.11,12 Currently, the World
Health Organization recommends use of the technique for
accurate staging of patients enrolled into clinical trials.
Ultimately dedicated HN studies definitively demonstrated
that SLNB is safe and reliable in the HN region,13–15 car-
rying the same false rate of emission of 4.2% as trunk and
extremity SLNB.16 The pathologic status of the sentinel
node is recognized as the most important prognostic fea-
ture for disease recurrence and overall survival.16
Current evidence based guidelines to include the
National Comprehensive Cancer Network recommend
CLND for all patients with a positive SLNB.8 The ratio-
nale for CLND is that uncontrolled regional disease will
ultimately lead to systemic metastasis with decreased
survival. However, this practice is variable and recent
studies challenge the need and associated benefit
afforded by CLND because patients with negative SLNB
are at risk for subsequent distant disease.17–19 This state
of the art review provides an evidence-based, contempo-
rary review of the utility of CLND for sentinel node posi-
tive HN cutaneous melanoma patients.
Current practice of CLND
Current National Comprehensive Cancer Network
(NCCN) guidelines advocate the use of SLNB for
patients with localized Stage I and II melanoma, as well
as patients with resectable satellite and in transit dis-
ease.8 Specifically, patients with Stage IB (0.76–1.0 mm
thickness with 1 mitotic feature/mm2 or Stage II
>1.0 mm thickness) should also be offered SLNB. Stage
IA patients (0.76–1.0 mm thickness in the absence of
ulceration and/or increased mitotic rate) should have the
opportunity to discuss and consider SLNB staging.
Per NCCN guidelines, patients with SLNB-positive
stage III nodal disease should be offered a CLND.8 Panel
members acknowledge the increased cost and morbidity
associated with immediate CLND. At the same time, they
highlight benefits of CLND to include: the increased known
probability of additional positive non-SLNs, improved
regional control, lower morbidity when compares to TLND,
and potential to improve long-term disease specific survival
(DSS) in these aggressive tumors.8
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While CLND following a positive SLNB is standard
of care, review of the National Cancer Data Base (2004–
2005) revealed only 50% of patients with a positive
SLNB undergoing CLND.20 Patients were more likely to
undergo CLND if care was rendered in an NCCN or
NCI-designated center; patients were more likely to be
observed if they were >75 years of age or had an
extremity melanoma.
Mosquiera et al. utilized the Surveillance Epidemi-
ology and End Results (SEER) registry to conduct a pop-
ulation based analysis of intermediate thickness (1–
4 mm depth of invasion) melanoma patients undergoing
CLND.21 Thirteen percent of the 2172 study patients
were primary HN. Ninety-one patients with HN mela-
noma underwent SLNB1 observation; 190 HN patients
underwent SLNB1CLND for regional disease. Overall,
68% of HN patients received CLND which mirrored that
of trunk melanoma (70%) but was significantly higher
than extremity melanoma (65%; p5 0.05). CLND corre-
lated with male gender (OR: 1.27), geographic location
(Michigan OR5 2.31; Iowa OR5 1.69), and younger age.
While male gender, primary site, ulceration, depth of
invasion, Clark level of invasion and number of positive
lymph nodes were associated with survival (p< 0.05),
CLND did not reach statistical significance (p5 0.83).
The study demonstrated <2% five-year DSS advantage
following CLND which was not significantly different
from observation alone (70.4 vs. 72.3; p50.83).
Prognostic Heterogeneity of SLN-Positive
Patients
Patients with a positive SLNB represent a hetero-
geneous cohort with survival rates ranging from a prom-
ising 90% to a dismal 30%.22 SLN tumor burden is a
recognized prognostic factor with high tumor volume
patients portending a worse prognosis.22–24 Tumor bur-
den is defined as the maximum diameter of the largest
metastatic deposit without lymphocytic interruption.
Consensus has not been reached as to the specific cut-
point between high versus low tumor burden. Several
studies demonstrate a similar disease-free survival
(DFS) and melanoma specific survival (MSS) rate
between SLN-negative and SLN-positive patients with
tumor burden measuring <0.1 mm.25–27 Scheri et al.
demonstrated a significant change in MSS when the
minimal tumor burden cut point was increased from
<0.1mm (90% MSS) to 0.2 mm (80% MSS).28 It is impor-
tant to note that SLN pathology sectioning protocols sig-
nificantly impact patients classified. Patients initially
deemed low SLN tumor burden (<0.1 mm) will actually
be harboring high tumor burden identified only after
additional SLN cuts are made for pathologic evalua-
tion.29 A current standardized pathology protocol for
assessing SLN tumor burden does not exist.30
Tumor penetrative depth (TPD) of the micrometastatic
disease within the SLN also impacts prognosis. The Dewar
Criteria classifies patients based on subcapsular anatomic
site.31 Subcapsular metastasis is defined as melanoma cells
confined to the subcapsular sinus or the paratrabecular
region without associated irregularity.31 This location is
found in approximately 20–30% of patients and portends
a better prognosis compared to metastatic melanoma
beyond the subcapsular region.29,31 Alternatively, the S-
classification divides TPD into three categories: S1
(0.3 mm), S2 (>0.3 to 1.0 mm) and S3 (>1.0 mm).24
Approximately 30% of SLN positive patients fall into the
S1 category and have an improved survival over S2 and
S3 metastatic deposits. The Rotterdam criteria is a simi-
lar classification with even integer TPD cut-points
(<0.1mm, 0.1–1.0 mm, >1.0 mm).32 Approximately 10–
15% of SLN positive patients harbor TPD <0.1 mm and
portend a better overall prognosis compared to deeper
TPD.
Van der Ploeg et al. combined the prognostic infor-
mation from both tumor burden utilizing the Dewar cri-
teria and TPD utilizing the Rotterdam criteria.28
Patients harboring <0.1 mm tumor burden confined to
the subcapsular region demonstrated an excellent over-
all melanoma specific survival (MSS) with 95% five-year
and 10-year rates. Unfortunately, only 6% of SLN posi-
tive patients fall into this specific category.
Therapeutic Value of CLND: Non-Randomized
Trials
Numerous single institution and non-randomized
trials investigated the survival benefit of CLND follow-
ing a positive SLNB. Bamboat et al. conducted a non-
randomized study of their Memorial Sloan-Kettering
Cancer Center (MSKCC) experience.33 Of their 4310
melanoma, 495 (11%) had a positive SLNB. 167 (34%)
underwent observation while the remaining 328 (66%)
underwent immediate CLND. There was no difference
between the two treatment arms with respect to tumor
depth of invasion, Clark’s level of invasion, or ulceration.
The observation arm was significantly older (66 years
vs. 56 years; p<0.001) and was more likely to have a
lower extremity melanoma. Patients had a minimum of
23 months follow-up in the observation arm and 80
months in the CLND arm. There was no difference in
local or in transit metastasis between the two groups.
Patients in the observation arm were more likely to
have a regional recurrence (15% vs. 6%; p50.002) while
patients in the CLND arm were more likely to develop
systemic recurrence (27% vs. 8%; p<0.001). Sixteen per-
cent of the SLN-positive patients who went on to CLND
had additional positive non-SLNs. Recurrence free
survival (RSS) rates were higher in the CLND arm
(34.5 vs. 20.9 months; p5 0.02) but MSS did not differ
(p5 0.09).
Wong et al. conducted a multi-institutional study
among 16 melanoma centers to determine the impact of
observation following a positive SLNB compared to his-
toric controls.34 The median age for the study cohort
was 59 years. The median depth of invasion was
2.6 mm. Seventy-seven percent of all tumors were classi-
fied as Clark level 4/5 and 33% of the tumors were ulcer-
ated. Only 12% of study patients had a primary
melanoma involving the HN region. 134 patients were
observed for a median period of 20 months which was
shorter than the 36-month follow-up for the 164 CLND.
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Overall, 20 patients (15%) in the observation arm went
on to develop nodal recurrence at a median time of 11
months. The nodal RFS did not differ between the obser-
vation and CLND cohorts (p5 0.07), and the DSS did
not differ between the groups (p5 0.65).
Kingham et al. conducted a prospective database
study (1992–2008).35 Of the 2269 patients undergoing
SLNB, 313 had at least one positive node. 271 (87%) of
patients received CLND, with the remaining 42 (13%)
were observed with serial ultrasound for the first two
years. Only 28 of the 313 patients (9%) were HN primar-
ies. Patients in the observation cohort were older (70
years vs. 56; p< 0.01) and were more likely to have an
extremity melanoma (40% vs. 13%; p< 0.01). Patient
refusal was the most common reason for observation
(45%). The observation cohort had a median follow-up of
32 months and the CLND cohort 43 months. No differ-
ence was identified between the two groups with respect
to location of first recurrence, RFS or DSS. Similarly, a
retrospective EORTC trial included 1174 positive SLNB
patients to compare CLND (n51113) to observation
(n5 61).36 CLND did not impact DSS on univariate and
multivariate analysis.
Therapeutic Value of CLND: Randomized Trials
DeCOG-SLT is a multicenter, phase III trial ran-
domizing SLN-positive patients to immediate CLND
(n5 241) versus observation with serial nodal ultra-
sound (n5 242).37 The primary endpoint was distant
metastasis-free survival. At a median follow-up of 35
months, the authors reported no difference in three-year
distant metastatic rates between the CLND arm (75%)
and the observation arm (77%). Similarly, CLND did not
impact RFS or overall survival (OS) beyond that of
observation. A slight improvement in regional control
was noted with CLND (92% vs. 85%). However multivar-
iate analysis failed to identify CLND as an independent
variable impacting distant metastatic-free survival, OS
or RFS. Overall, 34 (14%) of patients in the CLND arm
experienced complications to include: lymphedema
(n5 20; 58%), lymph fistula (n53; 8.8%), seroma (n5 3;
8.8%), infection (n53; 8.8%), and wound healing compli-
cations (n5 5;14.7%).
There are several limitations of the trial. 331
patients (66%) had low tumor burden SLNs measuring
1mm. The authors also acknowledge difficulties in
accrual, disclosing that the study was under powered.
The original study was planned for nine years, with an
accrual period of six years to enroll 550 patients and
detect a 10% difference in distant metastasis-free rate in
the setting of a CLND. After eight years of accrual, only
473 patient met inclusion criteria. Therefore, the princi-
ple investigators elected to close the trial early, acknowl-
edging that the study did not achieve the required
number of events.
DeCOG-SLT must be interpreted with caution for
HN cutaneous melanoma patients. Most importantly,
this study excluded the HN subsite because the authors
felt that the technique was “controversial” in the HN,
citing a review article from 2011.38 Since that
publication, the largest single institution, dedicated HN
melanoma SLNB study prospectively followed 353
patients for a mean of 48 months.16 Of patients with a
negative SLNB, 4.24% developed isolated regional recur-
rence. The negative predictive value for a negative HN
SLNB was reported as 95.8%, which mirrored that of
trunk and extremity melanoma where the technique is
considered standard of care.
Results of the long awaited Second Multicenter
Selective Lymphadenectomy Trial (MSLT-II) are pub-
lished.39 This international, multi-institutional random-
ized prospective trial was designed to determine the
value of CLND for patients with a positive SLN. From
2004–2014, 1934 were enrolled in the trial. Of these, 824
patients underwent SLNB1CLND and 931 underwent
SLNB1 observation. At a median follow-up of 43
months, the three-year MSS rate was similar between
the CLND and observations arms (68% vs. 86%;
p5 0.42). The CLND arm did experience an improved
DFS (68% vs. 64%; p5 0.05). Regional control was also
improved in the setting of CLND (92% vs. 77%;
p< 0.001). Of patients undergoing CLND, 11.5% had
additional positive non-SLNs identified on final pathol-
ogy, and a positive non-SLN was an independent prog-
nostic factor for recurrence (Hazard ration: 1.78;
p5 0.005). Overall, the MSLT-II research team conclude
that immediate CLND increased the rate of regional con-
trol and provided prognostic information but did not
impact MSS among melanoma patients with a positive
SLNB.
The clinical implications of this trial for HN cuta-
neous melanoma warrants several considerations. The
representation of the HN subsite was small. In the
MSLT-II trial, 241 patients had HN cutaneous mela-
noma (13.7%); 113 underwent CLND and 128 under-
went observation. Subgroup analysis of the three-year
hazards ratio for MSS was not found to differ based on
CLND (0.81; 0.44–1.48) versus observation following a
positive SLNB (1.60; 0.96–2.66; p5 0.07). In addition,
the authors stress the high rate of lymphedema follow-
ing CLND, a complication rarely seen in the HN region
(see below).
The European Organization for Research and Treat-
ment of Cancer (EORTC) Melanoma Group is currently
conducting the Minimal Sentinel Node Tumor Burden
(MINITUB) trial to investigate the ability for CLND to
portent a therapeutic benefit and to identify patients
who may potentially be spared the procedure without
oncologic compromise.40 The estimated enrollment is 260
SLN positive patients randomized to observation versus
CLND. Inclusion criteria are metastasis limited to the
SLN with either 1) subcapsular tumor burden 0.4 mm
and without parenchymal infiltration or 2) sub-
micrometastatic disease 0.1 mm regardless of node
subsite. The primary outcome measure is distant
metastasis-free interval. Secondary outcomes include:
regional control, relapse-free interval, MSS, OS, and
morbidity to include wound infection, lymphedema, and
neurological damage. Results from the trial are antici-
pated in 2023.
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CHALLENGES OF INTERPRETING THE
CURRENT CLND DATA
Paucity of Head and Neck–Specific Data
A paucity of data exists specific to HN cutaneous
melanoma CLND. As outlined above, large prospective
multi-institutional studies often lump the HN subset of
patients (who are known to carry a worse prognosis)
with trunk and extremity melanoma or exclude the site
altogether. Given small representation of HN patients in
CLND cutaneous melanoma studies, Lentsch et al. uti-
lized the SEER database to investigate the ability for
CLND to improve survival in the HN population.41
Three hundred fifty SLN positive patients were identi-
fied: 201 (60%) underwent SLNB1CLND while 140
(40%) received SLNB alone1 observation. Overall, a
five-year DSS was not imparted following CLND. How-
ever, a subset of younger patients (<60 years) with non-
ulcerated tumors measuring a depth of invasion 2 mm
benefited from immediate CLND (p5 0.03). Interest-
ingly, it is this same patient demographics that benefited
from END in the prior Intergroup Melanoma Surgical
Trial (IMST) back in 2000.42 This finding leaves in ques-
tion the ability to rely on prognostic features to forgo
CLND in the younger patient population; the authors
warn that younger patients traditionally deemed low
risk for metastatic recurrence may actually miss their
window for curative intervention if CLND is not
performed.
While the strength of this investigation is the spe-
cific focus on the HN subsite, the retrospective nature
inherent to database reviews remains a bias. In addi-
tion, the SEER database only represents 28% of the
patient population. Lastly, the authors acknowledge that
information is unavailable with respect to surgical mar-
gin status, adjuvant therapy, and the differentiation
between positive SLNs versus non-SLNs in the registry.
Lack of standardized pathology protocols for
evaluation of non-SLNs
Non-sentinel lymph node (non-SLN) status is another
recognized prognostic feature for the cutaneous HN mela-
noma patient population; however, the data is conflicting.43
Numerous studies attempted to identify SLN positive
patients who are at risk for additional positive non-SLNs
(identified following CLND). While primary tumor depth of
invasion and SLN characteristics (see above) have emerged
as prognostic markers in some investigations, the out-
comes are not consistently replicated. 44–46
In theory, patients with metastatic regional disease
limited to SLNs alone should receive the lowest benefit
from a CLND. The SEER database was utilized to test
this hypothesis specifically among HN melanoma
patients.47 The primary study objectives were 1) to iden-
tify prognostic features associated with a low risk for
harboring non-SLNs and 2) to analyze the five-year DSS
between patients stratified on risk for non-SLN positiv-
ity. Two hundred ten patients in the national database
received SLNB1CLND while 140 patients received
SLNB alone. Minimal tumor thickness (depth of
invasion) and non-ulceration were both associated with
a low risk of harboring non-SLN in the CLND specimen
(p< 0.25). Patient age, anatomic site, and sex were not
prognostic. Patients <60 years of age who underwent
CLND had a markedly improved DSS compared to
SLNB alone (>90% vs. <25%; p< 0.0025) but a DSS sur-
vival advantage with CLND over observation was not
found in the subgroup deemed at higher risk for non-
SLN metastasis (p> 0.25). The authors conclude that
selecting patients for CLND based on non-SLN risk of
metastasis may be unreliable.
MSLT-II found that patients with positive non-
SLNs portend a worse prognosis but at the current time
a reliable way to identify this high-risk subgroup is lack-
ing.39 A recognized challenge in identifying prognostic
models for non-SLN positivity is the lack of standardized
protocols for thorough evaluation of CLND nodes.
Wrightson et al. retrospectively reviewed 117 non-SLNs
harvested from 13 patients who underwent CLND fol-
lowing a positive SLN biopsy.48 Initially all 117 nodes
harvested during CLND were deemed negative for
metastasis on traditional hematoxylin and eosin stain-
ing. However, 18 (15%) of the nodes were reclassified as
positive following examination with reverse transcrip-
tion polymerase chain reaction. This change led to a
staggering 7 of the 13 patients (54%) being reclassified
as having positive non-SLNs.
Completion Lymphadenectomy Complications
The overall complication rates associated with
CLND are extremely variable, ranging from 20% to
60%.8 Proponents for observation over CLND cite the
higher complications rates and associated morbidity as
part of their rationale. Complications associated with
CLND include: wound infection/dehiscence, hematoma,
seroma, neuropathy, lymphocele, and lymphedema.
Lymphedema can impact as many as 50% of patients
and carries an association with obesity, age, and groin
dissection.8
Moody et al. conducted a systematic review of the
literature to investigate the associated postoperative
morbidity associated with a CLND following SLNB com-
pared to a TLND following regional recurrence in
patients observed following a positive SLNB.49 Eighteen
articles met inclusion criteria. A surgical complication
rate of 39.3% was reported in the 1627 undergoing
TLND which mirrored the 37.2% reported among 1929
patients receiving CLND.
The applicability of the above cite complications
within the HN patient population remains in question.
The most recent MSLT-II trial reported a statistically
higher rate of lymphedema in the setting of CLND
(24.1%) compared to 6.3% in the observation arm
(p< 0.001).39 However, lymphedema is a known compli-
cation of groin and extremity CLND, but does not carry
the same challenges for the neck.
CONCLUSIONS AND FUTURE ENDEAVORS
The data surrounding the need for CLND following
a positive SLNB remains controversial. HN cutaneous
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melanoma patients are a unique subset, carrying a
worse prognosis compared to their trunk and extremity
counterparts. In addition, they do not traditionally suffer
from the lymphedema often seen at other sites. The
importance of achieving regional control in the head and
neck given proximity to critical structures (carotid
artery, trachea, esophagus) bears thoughtful consider-
ation. Regional failure in the head and neck can have
significant implications on both quality and quantity of
life.
In order to truly determine the therapeutic utility
of SLNB, large, prospective, randomized trials specific to
the HN cutaneous melanoma population are required.
Prior to conducting such trials, a standardized, evidence-
based pathology protocol to evaluate of non-SLNs in a
meticulous fashion with incorporation of molecular
analysis are also required. In the interim, surgeons
should have a candid conversation with their HN mela-
noma patients about CLND. Ultimately the decision will
be made based on surgeon experience and patient
preference.
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